TetrAnflu

**TetrAnflu** is a quadrivalent inactivated split-virion influenza vaccine developed by Sinovac Biotech Ltd. for active immunization against influenza A (H1N1 and H3N2) and B (Victoria and Yamagata lineages) virus strains recommended annually by the WHO. Produced via chicken embryo culture, inactivation, purification, and disruption, it induces humoral antibody responses to prevent symptomatic influenza infection, with demonstrated immunogenicity superior to comparators in clinical studies and seroprotection rates up to 99.4%. It features a preservative-free formulation with stringent purity standards exceeding Chinese and European pharmacopeia limits, and has been administered in nearly 100 million doses worldwide, approved in China (including for ages 6 months+), Hong Kong, Bangladesh, and the Dominican Republic.[2][6][9]

Brand names

TetrAnflu

Other names

Influenza Virus Split Vaccine QuadrivalentInfluenza Vaccine (Split Virion), Inactivated, Quadrivalent